|
Oral Health, Cancer Care, and You
|
Public Education Campaign
|
CDC
|
NIDCR
|
A series of publications to inform health care providers and patients about steps they can take before, during, and after cancer treatment to reduce the risk and impact of these often painful side effects.
|
|
Osteoporosis and Related Bone Diseases—National Resource Center
|
Resource Development
|
OS, OSG
|
NIAMS, NIA, NICHD, NIDCR, NIDDK, OD
|
Provides patients, health professionals, and the public with an important link to resources and information on metabolic bone diseases, including osteoporosis, Paget’s disease of the bone, and osteogenesis imperfecta.
|
|
Package and Distribution of Nutritional Biochemistry for AREDS 2
|
Research Initiative
|
OS
|
NEI
|
AREDS2 is a multi-center randomized trial designed to assess the effects of oral supplementation of high doses of macular xanthophylls (lutein and zeaxanthin) and/or omega-3 LCPUFAs (DHA and EPA) for the treatment of AMD and cataract. The primary objective of AREDS2 is to evaluate the effect of dietary xanthophylls (lutein/zeaxanthin) and/or omega-3 LCPUFAs (DHA and EPA) on progression to advanced AMD. This objective will be accomplished by collecting and assessing the data on approximately 4,000 AREDS2 participants aged 50 to 85 years, who at the time of enrollment have either: 1) bilateral large drusen or 2) large drusen in one eye and advanced AMD (neovascular AMD or central geographic atrophy) in the fellow eye.
|
|
PACT (Production Assistance for Cellular Therapies) Workshop - Cell Therapy for Pediatric Diseases: A Growing Frontier
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NHLBI
|
The purpose of the workshop is to discuss strategies for overcoming barriers that impede the development and delivery of cell-based therapies for pediatric patients, in particular those with rare and life-threatening diseases. The participants will consider clinical applications of cellular therapies and regenerative medicine, including ethical considerations and models of clinical trial design.
|
|
Partners in Information Access for the Public Health Workforce
|
Resource Development
|
AHRQ, CDC, HRSA, OS
|
NLM
|
Partners in Information Access for the Public Health Workforce is a collaboration of U.S. government agencies, public health organizations, and health sciences libraries which provides timely, convenient access to selected public health resources on the Internet.
|
|
Partnerships to Address Cardiovascular Health Disparities
|
Training Initiative
|
HRSA
|
NHLBI
|
This partnership was established to test prevention strategies to address cardiovascular disease using community health workers.
|
|
Pathways of Diagnosis, Treatment, and Medical Service Utilization in Medicare and Medicaid Population
|
Research Initiative
|
CMS
|
CC
|
CMS and NIH CC/RMD agree to collaborate in data-sharing for research the results of which may be helpful to improve medical-service quality, utilization, and effectiveness for Medicare and Medicaid beneficiaries. CMS will provide electronic data to NIH CC/RMD who will perform analyses that are agreed to by both parties.
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS)
|
Research Initiative
|
FDA
|
NICHD, NCCAM, NCI, NHLBI, NIAID, NIAMS, NIDA, NIDDK, NIGMS, NIMH, NINDS, OD
|
The Patient-Reported Outcomes Measurement Information System (PROMIS) is a network of NIH-funded primary research sites and coordinating centers working collaboratively to develop a series of dynamic tools to reliably and validly measure patient-reported outcomes (PROs). PROMIS provides an opportunity to improve healthcare outcomes by giving decision makers hard data on how healthcare affects what patients are able to do and how they feel. The FDA has been invited to contribute to the scientific steering committee meetings as an interested partner.
|
|
Pediatric Emergency Care Applied Research Network (PECARN)
|
Research Initiative
|
HRSA
|
NICHD
|
Study of resuscitation practice and relationship to fulminant cerebral edema. PCCR program director is program official for the trial. This is a multisite clinical trial. The application was received as part of PAR HD 08-261/Emergency Medical Services for Children (EMSC).
|
|
Pediatric Formulations Platform
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NINR
|
This IAA is a collaboration between NICHD and the Center for Drug Evaluation and Research, FDA. The purpose is to create an open-source, publicly available oral pediatric formulations platform. This platform will designate specific formulation technologies, given the molecular and chemical properties of the drug and specific desired properties of the dosage form. The ideal pediatric dosage form would be an orally dissolvable solid; tasteless; in an appropriate dose amount that would be appropriate for infants; contain minimal amounts of safe excipients; stable in light, humidity, and heat; and have the necessary release characteristics, as applicable.
|